GLP1 Updates in Kidney Disease: An Interview
Glucagon-like peptide 1 receptor agonists (GLP1-RAs) are revolutionizing the treatment of obesity and related illnesses, including kidney disease. Two recent papers published in AJKD — an Original Investigation by Neumiller et al and a Mini Review by Friedman et al — examine GLP1s and their impacts on people with type 2 diabetes mellitus and progression to chronic kidney disease, and discuss the underlying mechanisms for these results.

Unifying model describing weight loss–independent kidney protective mechanisms of GLP-1 receptor agonists based on in vitro evidence. Abbreviations: AMPK, AMP-activated protein kinase; GLP-1, glucagon-like peptide-1; mTOR, mammalian target of rapamycin; PI3K, phosphoinositide 3-kinase; SIRT1, sirtuin 1. Figure 1 from Friedman et al, © National Kidney Foundation.
AJKDBlog’s Interviews Editor Timothy Yau recently chatted with Dr. Charbel Khoury about glucagon-like peptide 1 receptor agonists and what they mean for nephrologists.
If the embedded player above doesn’t work, please click here to watch the video interview. Special thanks to Dr. Khoury for his time and insight!
To view Neumiller et al [Subscription Required], please visit AJKD.org:
Title: Comparison of Specific Glucagon-Like Peptide-1 Receptor Agonists on Kidney Outcomes Among Patients With Type 2 Diabetes
Authors: Joshua J. Neumiller, Yihong Deng, Kavya Sindhu Swarna, Eric C. Polley, Jeph Herrin, Rodolfo J. Galindo, Guillermo E. Umpierrez, Joseph S. Ross, Mindy M. Mickelson, Kate Dryden, Katherine R. Tuttle, Rozalina G. McCoy
DOI: 10.1053/j.ajkd.2026.04.007
To view Friedman et al [Free], please visit AJKD.org:
Title: Weight Loss–Independent Mechanisms of Kidney Protection With Glucagon-Like Peptide 1 Receptor Agonists and Implications for Clinical Practice
Authors: Allon N. Friedman, Ilyas Oultache, Robert Hovey
DOI: 10.1053/j.ajkd.2026.03.037
Leave a Reply